Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadastuximab Talirine + Azacitidine in Untreated MDS
NCT02706899Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Feb 2016
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing 33A + azacitidine with Placebo + azacitidine (2 arms). Primary endpoints: Recommended Dose of Vadastuximab Talirine for the Phase 2 Portion of the Study up to 1 year and Overall Response Rate for the Phase 2 Portion of the Study. Started Feb 2016; status: terminated.
02
Drugs
vadastuximab talirine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02706899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706899.